Group 1 - The company reported a revenue of 32.245 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 122.84% [1] - Gross profit for the same period was also 32.245 million RMB, showing a year-on-year increase of 128.35% [1] Group 2 - The company has successfully implemented a light asset operation model, effectively reducing operational costs [2] - The company is actively pursuing strategic partnerships and has submitted a new listing application for a proposed merger to the Stock Exchange [2] - The innovative drug, GB491 (salt of Luroxil), received approval from NMPA on May 27, 2025, for specific indications related to breast cancer treatment [2] - An exclusive委托协议 has been established with Yiteng Pharmaceutical for the commercialization and national medical insurance directory application of GB491 [2] - The company has initiated the FIH clinical trial for its core pipeline product GB268, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, after receiving NMPA approval [2] - Clinical trials for GB261, a bispecific antibody for autoimmune diseases, have commenced outside the Greater China region [2]
嘉和生物-B(06998)发布中期业绩 毛利3224.5万元 同比增加128.35%